Evaluating multiple surrogate markers with censored data

DOI10.1111/biom.13370zbMath1520.62300OpenAlexW3085769367WikidataQ99401204 ScholiaQ99401204MaRDI QIDQ6055488

L. Tian, Layla Parast, Tianxi Cai

Publication date: 30 October 2023

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162900

zbMATH Keywords

survivalclinical trialstreatment effectinverse probability weightingdouble robustsurrogate marker

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Related Items

Robust Approach to Combining Multiple Markers to Improve Surrogacy

Cites Work

• Unnamed Item
• Unnamed Item
• Doubly Robust Estimation in Missing Data and Causal Inference Models
• Inconsistency of the misspecified proportional hazards model
• The evaluation of surrogate endpoints.
• Surrogate Measures and Consistent Surrogates
• Improved double-robust estimation in missing data and causal inference models
• Comparing Biomarkers as Principal Surrogate Endpoints
• The Evaluation of Multiple Surrogate Endpoints
• A Measure of the Proportion of Treatment Effect Explained by a Surrogate Marker
• On the relationship between the causal‐inference and meta‐analytic paradigms for the validation of surrogate endpoints
• The loss in efficiency from misspecifying covariates in proportional hazards regression models
• On Inference in Parametric Survival Data Models
• Accounting for the Black–White Wealth Gap
• Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
• Approximate Residual Balancing: Debiased Inference of Average Treatment Effects in High Dimensions
• Landmark Estimation of Survival and Treatment Effect in a Randomized Clinical Trial
• Estimation and inference for the indirect effect in high-dimensional linear mediation models
• Model-free approach to quantifying the proportion of treatment effect explained by a surrogate marker